Email this article 
SOLUBLE FORMS OF IMMUNE CHECK-POINT RECEPTOR PD-1 AND ITS LIGAND PD-L1 IN PERIPHERAL BLOOD OF ONCOLOGIC PATIENTS: CLINICAL AND PATHOLOGIC CORRELATIONS
- Authors: Alferov AA1, Gershtein ES1, Naberezhnov DS1, Goryatcheva IO1, Kushlinskii NE1
-
Affiliations:
- N.N. Blokhin National Medical Research Center of Oncology
- Issue: Vol 19, No 1S (2019)
- Pages: 8-9
- Section: Articles
- URL: https://journals.eco-vector.com/MAJ/article/view/19293
- ID: 19293
Cite item
Full Text
Abstract
The levels proteins of control points of immunity sPD-1, sPD-L1 in serum or plasma of 366 patients with malignant tumors of various nosological forms treated at the N.N. Blokhin National Medical Research Center of Oncology. A correlation of sPD-L1 with the prevalence of the process and the degree of tumor malignancy, as well as a positive correlation with some other tumor markers of blood, was found: VEGF, VEGFR1, MMP-7, MMP-8, TIMP-1.
Keywords
sPD-L1, sPD-1, VEGF, VEGFR1, MMP-7, MMP-8, TIMP-1, sPD-1, sPD-L1, VEGF, VEGFR1, MMP-7, MMP-8, TIMP-1, kidney cancer, ovarian cancer, gastric cancer, bone sarcomas, blood serum, blood plasma
Full Text
Among various possibilities of escaping from antitumor immunity an important role belongs to modification of PD-1/PD-L immune check-point signaling pathway. Tumor PD-1 and/or PD-L1 expression is investigated both as a predictor of corresponding immunotherapy efficiency, and as molecular marker of overall prognosis and patients’ survival. This goal could be also attained by measurement of soluble forms of these proteins in peripheral blood. Serum or plasma sPD-1 and sPD-L1 content was measured with standard ELISA kits (Affimetrix) in 117 patients with renal and 121 with ovarian tumors, 70 with gastric cancer, 58 with bone sarcomas, and 74 practically healthy persons. sPD-L1 in blood serum of renal cancer patients was significantly higher than in control (p < 0.001). It significantly increased with disease stage and T index, was higher in patients with N1 or N2 lymph node status than in those with N0; increased in М+ patients, and at GIII-IV as compared to GI-II tumors. It was also positively associated with VEGF, VEGFR1, MMP-7, MMP-8 and TIMP-1 serum levels. In gastric cancer and bone sarcomas sPD-L1 was increased as compared to control. In ovarian cancer sPD-L1 level did not differ from control, but significantly increased with disease stage. sPD-1 concentrations did not differ significantly between study groups. Thus, sPD-L1 is increased in patients with various malignant tumors, correlates with diseaseprogression and tumor grade, and can be regarded as promising marker for monitoring of anti-PD1/PD-L treatment. Supported by RFBR grant 18-03-00793.×
About the authors
A A Alferov
N.N. Blokhin National Medical Research Center of Oncology
E S Gershtein
N.N. Blokhin National Medical Research Center of Oncology
D S Naberezhnov
N.N. Blokhin National Medical Research Center of Oncology
I O Goryatcheva
N.N. Blokhin National Medical Research Center of Oncology
N E Kushlinskii
N.N. Blokhin National Medical Research Center of Oncology
References
Supplementary files
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).